scholarly journals A placebo‐controlled proof‐of‐concept study of alirocumab on postprandial lipids and vascular elasticity in insulin‐treated patients with type 2 diabetes mellitus

2020 ◽  
Vol 22 (5) ◽  
pp. 807-816 ◽  
Author(s):  
Benjamin Burggraaf ◽  
Nadine M.C. Pouw ◽  
Salvador Fernández Arroyo ◽  
Leonie C. Vark‐van der Zee ◽  
Gert‐Jan M. Geijn ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Proof Of Concept ◽  
Concept Study ◽  
Vascular Elasticity ◽  
Postprandial Lipids

Author response for "A Placebo‐controlled Proof‐of‐Concept Study of Alirocumab on Postprandial Lipids and Vascular Elasticity in Insulin‐treated patients with Type 2 Diabetes Mellitus"

2019 ◽  
Author(s):  
Benjamin Burggraaf ◽  
Nadine Pouw ◽  
Salvador Fernández Arroyo ◽  
Leonie C. van Vark‐van der Zee LC ◽  
Gert‐Jan M. Geijn ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Author Response ◽  
Proof Of Concept ◽  
Concept Study ◽  
Vascular Elasticity ◽  
Postprandial Lipids

scholarly journals Carbohydrate restricted diet in conjunction with metformin and liraglutide is an effective treatment in patients with deteriorated type 2 diabetes mellitus: Proof-of-concept study

2011 ◽  
Vol 8 (1) ◽  
pp. 92 ◽  
Author(s):  
Jürgen E Müller ◽  
Dagmar Sträter-Müller ◽  
Hans-Joachim Marks ◽  
Michael Gläsner ◽  
Philipp Kneppe ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Effective Treatment ◽  
Proof Of Concept ◽  
Restricted Diet ◽  
Concept Study

scholarly journals LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

2018 ◽  
Vol 18 ◽  
pp. 3-14 ◽  
Author(s):  
Tamer Coskun ◽  
Kyle W. Sloop ◽  
Corina Loghin ◽  
Jorge Alsina-Fernandez ◽  
Shweta Urva ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Receptor Agonist ◽  
Proof Of Concept

In-silico Exploration of Phytoconstituents of Gymnema sylvestre as Potential Glucokinase Activators and DPP-IV Inhibitors for the future Synthesis of Silver Nanoparticles for the Treatment of Type 2 Diabetes Mellitus

2021 ◽  
Vol 17 ◽  
Author(s):  
Ajinkya B. Chavan ◽  
Kratika Daniel ◽  
Ansar M. Patel
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Silver Nanoparticles ◽  
Type 2 Diabetes Mellitus ◽  
Preliminary Investigation ◽  
Gymnema Sylvestre ◽  
Proof Of Concept ◽  
Dpp Iv ◽  
Glucokinase Activators

Background: Diabetes has a large death toll worldwide, particularly as it falls into the ten leading causes of death. Type 2 diabetes mellitus (T2DM) occurs as the body becomes resistant to insulin and sugar accumulates in the blood. It has been observed that, dipeptidyl peptidase-IV (DPP-IV) inhibitors and glucokinase activators are known therapeutic agents to treat T2DM. Among the possible medicinal plants, Gymnema sylvestre (GyS) belongs to the Apocynaceae family and is traditionally used for the treatment of different diseases. This plant is also known as 'Gurmur' because it has a sugar reducing ability. GyS was known to be one of the main botanicals for the treatment of diabetes. Objective: Rendering to the studies described above, we have tried to investigate the natural DPP-IV inhibitors and potent glucokinase activators from the phytoconstituents of GyS. New drug candidates from the medicinal plant GyS have been reported as potent DPP-IV inhibitors and glucokinase activators. Methods: As a preliminary investigation, we have studied the effectiveness of phytoconstituents of GyS in T2DM through molecular docking as a proof of concept of synthesizing silver nanoparticles (for the treatment of T2DM) using extract of this plant. Results: The present investigative research showed that diabetes mellitus has important values in the recognized compounds included in the present analysis. The nine compounds selected were evaluated on the basis of DPP-IV and glucokinase enzyme binding energy values and their drug properties. Except quercitol, all the selected compounds have exhibited very potent glucokinase activation potential than its native ligand. Gymnemasin A, lupeol, gymnemoside A, gymnemasaponin V and gymnemic acid I have shown excellent DPP-IV inhibitory potential. Conclusion: We are aiming to synthesis the silver nanoparticles of leaf extract of GyS for the treatment of T2DM. As a preliminary investigation, we have studied the effectiveness of phytoconstituents of GyS in T2DM through molecular docking as a proof of concept of synthesizing silver nanoparticles (for the treatment of T2DM) using extract of this plant. As a result of present investigation, it has been concluded that these compounds can be used to treat the T2DM and hence in future we will synthesize the silver nanoparticles of GyS extract for the treatment of T2DM.

Effect of pioglitazone treatment on brown adipose tissue volume and activity and hypothalamic gliosis in patients with type 2 diabetes mellitus: a proof-of-concept study

2019 ◽  
Vol 56 (12) ◽  
pp. 1333-1339 ◽  
Author(s):  
José C. de-Lima-Júnior ◽  
Sylka Rodovalho ◽  
Simone Van de Sande-Lee ◽  
Milena Monfort-Pires ◽  
Briana Rachid ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Adipose Tissue ◽  
Brown Adipose Tissue ◽  
Proof Of Concept ◽  
Brown Adipose ◽  
Adipose Tissue Volume ◽  
Pioglitazone Treatment
Sign in / Sign up

Export Citation Format

Share Document